Merck CFO: we’re not only about Keytruda

Predictably, discussion of Keytruda’s massive clinical trials programme dominated Merck’s third-quarter results call. However chief financial officer Rob Davis (pictured left) stressed that Rob Davis“while Keytruda is truly a foundational product, we are a lot more than just Keytruda”.